CYNO Cynosure - Class A (MM)

Company Launches Smartlipo MPX Laser Lipolysis Workstation in Korea; Secures Market Approval for Affirm Skin Rejuvenation Technology in China WESTFORD, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Broadening the reach of two of its flagship aesthetic laser products into the Asia Pacific region, Cynosure, Inc. (NASDAQ:CYNO) today announced that it has received approval to market the Smartlipo MPX(TM) LaserBodySculpting(SM) Workstation in Korea and the Affirm(TM) Anti-Aging Workstation in the People's Republic of China. Smartlipo MPX is the world's signature brand for precision body contouring; Affirm provides a complete skin rejuvenation solution that targets all layers of photodamaged and aged skin. "These approvals for Smartlipo MPX and Affirm further our initiative to expand in the Asia Pacific region as part of our international growth strategy," said Cynosure President and Chief Executive Officer Michael Davin. "We believe that the increasing economic prosperity of the middle class in these countries is creating a vibrant base of aesthetically conscious consumers and a corresponding demand from practitioners eager to be trained on new procedures and techniques. By having already established a direct sales presence in China and Korea, we believe we are well positioned to capitalize on opportunities through new product introductions in these dynamic markets." Smartlipo MPX and Affirm are among Cynosure's most popular workstations. Smartlipo MPX liquefies fat and tightens skin through tissue coagulation. The novel Smartlipo MPX platform incorporates the company's exclusive MultiPlex(TM) technology. MultiPlex combines the benefits of the 1064-nm and 1320-nm wavelengths in a single laser output, creating a blended thermal and photomechanical effect. The Smartlipo MPX workstation can be configured with the company's SmartSense with ThermaGuide, an intelligent energy delivery system equipped with a thermal sensing cannula for controlling temperatures in the subcutaneous areas of the body. This technology allows the practitioner to set temperature thresholds to achieve targeted, controlled energy delivery for a safe and optimal clinical endpoint. The non-invasive Affirm Anti-Aging Workstation offers the benefits of wrinkle reduction, pigmentation and redness reduction, age spot treatment and overall facial rejuvenation. The MultiPlex technology-equipped Affirm enables the sequential emission of two wavelengths in one pulse from the same delivery system, helping to maximize comfort and achieve faster recovery time compared with single-wavelength technologies. Affirm uses the 1440-nm Combined Apex Pulse(SM) technology to target superficial layers of photodamaged tissue, state-of-the-art Xenon Pulsed Light technology to enhance clinical outcomes associated with the treatment of redness and pigmentation, and 1320-nm MultiPlex technology to target deep layers of collagen structures for skin laxity and tightening. About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com/. Safe Harbor Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's plans within the People's Republic of China and Korea, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617.542.5300 DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President, Sharon Merrill Associates, Inc. for Cynosure, Inc., +1-617-542-5300, Web Site: http://www.cynosurelaser.com/

Copyright